Shots:

• The approval was based on the open-label, international multicenter study to evaluate the efficacy and safety of Vonvendi in 10 adult patients with severe Type 3 VWD who have received on-demand therapy
• The results showed a 54.7% reduction in median annualized bleeding rates (ABR) for all bleeds (treated/untreated spontaneous and traumatic bleeding events)
• Vonvendi is the 1st FDA approved recombinant VWF replacement therapy which is designed to reduce the frequency of bleeding episodes for severe Type 3 VWD for routine prophylactic use in adults who received on-demand therapy along with perioperative bleed management to treat VWD

Ref: Businesswire | Image:Takeda